T

Tenvie Therapeutics

Develops precision CNS-penetrant small molecules

Clinical Development Scientist - Senior Clinical Development Scientist

Full-Time
$125k - $180k/yr
Mid, Senior
PharmD, PhD, MD
Brisbane, CA, USA
HybridThe role may be remote, hybrid, or on-site.

About the job

Requirements
  • Typically 3–7+ years of relevant experience in clinical development, clinical pharmacology, or translational medicine within biotech/pharma or an equivalent academic clinical research environment.
  • Demonstrated experience contributing to the design and execution of early-phase Phase 1–2 clinical trials.
  • Experience working on cross-functional teams with Clinical Operations, Biometrics, Regulatory, and Translational or Discovery functions.
  • Strong understanding of clinical trial methodology, Good Clinical Practice, and the overall drug development pathway from first-in-human through proof-of-concept.
  • Comfort interpreting pharmacokinetic/pharmacodynamic, biomarker, and clinical efficacy and safety data, and working with statisticians and pharmacometricians.
  • Strong scientific writing skills with a track record of producing clear, structured documents and presentations.
  • Ability to manage multiple studies or workstreams in parallel in a fast-paced environment.
  • Strong analytical and critical-thinking skills, with the ability to turn complex data into clear, actionable recommendations.
  • Ability to tailor scientific messages to clinicians, scientists, operations personnel, leadership, and regulators.
  • Ability to work collaboratively across disciplines and with external partners.
  • Commitment to high ethical standards, patient safety, and data integrity.
Responsibilities
  • Author or co-author clinical sections of protocols, protocol amendments, investigator brochures, informed consent forms, clinical and scientific training materials, medical monitoring plans, and safety review or dose-escalation committee charters.
  • Translate protocol intent into operational deliverables such as case report forms, electronic case report form completion guidelines, and laboratory and pharmacy manuals.
  • Develop or contribute to study-level documents, including medical monitoring plans, safety review or dose-escalation committee charters, data review plans, and statistical analysis plans.
  • Draft and review clinical sections of regulatory documents and responses, including Health Authority interactions, briefing books, investigational new drug and annual reports, and safety updates.
  • Serve as Clinical Scientist lead on cross-functional study teams for selected trials.
  • Provide clinical and scientific input into site selection, eligibility reviews, and key study tools such as manuals, training decks, and case report forms.
  • Perform routine reviews of patient profiles, listings, coded terms, and narratives; monitor trends across safety, efficacy, and protocol compliance; and help define and track key data review listings and visualizations.
  • Contribute to the interpretation of emerging clinical safety and efficacy data.
  • Support the development and execution of safety review or dose-escalation committees and data monitoring activities.
  • Lead or co-lead integrated analyses of clinical safety and efficacy, pharmacokinetic/pharmacodynamic, and biomarker data to generate conclusions and next-step recommendations.
  • Prepare data summaries and presentations for internal governance, external collaborators, and advisory boards.
  • Lead clinical study report authoring.
  • Contribute to abstracts, posters, and manuscripts for scientific meetings and peer-reviewed journals.
  • Provide scientific support to investigators and study sites through training, protocol clarification, and scientific questions and answers.
  • Participate in key opinion leader and expert advisory boards, contributing to agendas, content, and follow-up.
  • Collaborate with contract research organizations, central laboratories, imaging and biomarker vendors, and other partners to align scientific and operational expectations.
  • Support the development of clinical development plans, target product profiles, and indication prioritization.
  • Lead or co-lead the scientific design of Phase 1–2 studies, including first-in-human, dose-finding, and proof-of-concept studies, objectives, endpoints, inclusion and exclusion criteria, and biomarker strategy.
  • Integrate nonclinical, translational, and clinical data to inform dose selection, schedule, and patient population.
  • Help shape clinical development best practices, templates, and processes across the portfolio.
  • Model scientific rigor, transparency, and cross-functional collaboration.
Desired Qualifications
  • PharmD or PhD in life sciences, pharmacology, physiology, or a related field.
  • MD or equivalent clinical degree.
  • Strong foundation in cardiometabolic biology, including obesity, insulin resistance, dyslipidemia, NAFLD/NASH, and cardiovascular risk.
  • Strong foundation in neuroinflammation, including neurodegeneration and neuropathic pain.
  • Cardiometabolic, obesity, and/or neurologic clinical trial experience.
  • Prior involvement in regulatory submissions, including investigational new drug or clinical trial applications, briefing packages, and responses to queries.

About the company

Tenvie Therapeutics develops small-molecule drugs aimed at neurological diseases, with a focus on molecules designed to cross the blood-brain barrier and reach the central nervous system effectively. Its leading strategy is to optimize molecular delivery properties so CNS penetration is improved, maximizing benefits for patients. The company maintains a diverse pipeline of proprietary assets, including programs acquired from Denali Therapeutics, and monetizes its work by advancing these CNS-targeted therapies in clinical development. Led by President and Chief Scientific Officer Tony Estrada, the team emphasizes CNS drug development expertise to pursue patient-focused outcomes.

Company Size

51-200

Company Stage

Early VC

Total Funding

$200M

Headquarters

Brisbane, California

Founded

2025

Get referred to Tenvie Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • April 2026 first doses for TNV262 and TNV108 de-risk Tenvie's platform execution.
  • June 18, 2026 UBS highlights Q4 biomarker data for TNV262's obesity and cardiovascular thesis.
  • February 18, 2026 Don O'Sullivan joined as CBO, strengthening partnering and financing.

What critics are saying

  • TNV262 and TNV108 remain Phase 1 assets; 2026 readouts decide the company.
  • Obesity, cardiovascular disease, MS, and neuropathy already attract Novo Nordisk, Roche, and AbbVie.
  • If Q4 2026 biomarker data disappoints, Tenvie loses its CNS-penetration story and funding.

What makes Tenvie Therapeutics unique

  • Tenvie builds precision-engineered, CNS-penetrant small molecules, not biologics, for neurological disease.
  • Its pipeline includes Denali-acquired assets, giving immediate depth and validated neuroscience chemistry.
  • By April 2026, both TNV262 and TNV108 had reached Phase 1.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

↑ 18%

1 year growth

↑ 18%

2 year growth

↑ 4%
GlobeNewswire
Jul 23rd, 2025
Tenvie Therapeutics Promotes Tony Estrada, PhD, to Chief Executive Officer

Tenvie Therapeutics promotes Tony Estrada, phd, to Chief Executive Officer.

DealForma
Jan 15th, 2025
Verdiva Bio Launches with $411M Series A

In Q1 2025, biopharma venture funding surged, with Verdiva Bio launching with a $411 million series A, co-led by Forbion and General Atlantic, to develop therapies for obesity and cardiometabolic diseases. Other notable funding rounds included Aviceda Therapeutics' $208 million series C, Abcuro's $200 million series C, Windward Bio's $200 million series A, and Tenvie Therapeutics' $200 million seed funding.

STAT
Jan 8th, 2025
Denali Therapeutics spinout raises $200M as neuro company resets

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug candidates.

GlobeNewswire
Jan 8th, 2025
Tenvie Therapeutics Launches with $200 Million to Deliver Breakthrough Small Molecule Therapies

Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases Led by expert R&D leadership team...